A double blind, randomized, cross-over placebo controlled study to investigate the efficacy of sublingual testosterone solution on physiological and subjective arousal in healthy, sexually dysfunctional premenopausal women. - PD-Testosterone

Emotional Brain0 个研究点目标入组 16 人开始时间: 待定最近更新: 2024年5月6日

适应症

试验速览

暂无简介。

•1. Provision of written informed consent;
•2. Female 21-40 years of age with Hypoactive Sexual Desire Disorder (comorbidity with other sexual dysfunctions e.g Female Sexual Arousal Disorder (FSAD) is allowed).
•3. Healthy according to normal results of medical history, physical examination, laboratory values and vital signs, unless the investigator considers an abnormality to be clinically relevant;
•4. Subject must be heterosexually oriented;
•5. BMI >= 18 and <= 30 kg/m2.

•1. A history of Childhood Sexual Abuse;
•2. Subjects who had used testosterone therapy within 6 months before study entry;
•3. Use of oral contraception containing anti-androgens (e.g. Diane 35; Minerva);
•4. Use of oral contraception containing 50 µg estrogen or more;
•5. Pregnancy, or intention to become pregnant during this study (Note: a serum or urine pregnancy test will be performed in all women prior to the administration of study medications);
•6. Lactating, or subjects who have given birth in the previous 6 months;
•7. Subjects who are taking CYP3A4-inhibitors: ritonavir (HIV-proteaseremmer), ketoconazol en itraconazol claritromycine, erytromycine and saquinavir;
•8. Subjects who are taking CYP3A4-inducers: carbamazepine, fenytoïne, fenobarbital, st Johns Wort, rifampicine;
•9. A substance abuse disorder that in the opinion of the investigator is likely to affect the subject's ability to complete the study or precludes the subject*s participation in the study; mild or moderately alcohol drinking behavior is allowed, only 24 hours before the experimental days is alcohol drinking not allowed. Three weeks before the start of the experimental day is the taking of any recreational drug not allowed. Smoking is allowed.
•10. Subjects with a peri menopausal hormonal status (FSH > 30).

发起方